CA-NITRO-SOFTWARE
16.3.2023 01:05:39 CET | Business Wire | Press release
Nitro Software, a global leader in SaaS eSignature and PDF document solutions for businesses, announced today that Nitro Sign was again named a Leader in the GigaOm Radar Report for E-Signature Solutions.
Nitro Sign provides organizations with high-trust electronic signatures that meet or exceed global security and compliance standards, including multiple layers of protection and identity verification. The scalable solution also offers flexible integrations and APIs.
Identifying Nitro Sign as an industry Leader for the second year in a row, GigaOm acknowledged that the Nitro platform supports highly secure, end-to-end digital document processes with a seamless customer experience.
GigaOm’s 2023 Radar Report for E-Signature Solutions awarded Nitro Sign high scores for its:
- extensive compliance support, offering direct eID integration for over 30 jurisdictions
- leading data field configuration and analytics functionality
- best-in-class pricing tiers with minimal add-on fees
- automation and digitization across document workflows
- scalability and security due to its high-trust global data center strategy, extensive security provisions and tamper-proof seals at the signature (rather than envelope) level
GigaOm also noted that Nitro’s broad portfolio can support even the most complex use cases.
“The global adoption of eSignatures took off during the pandemic, and it only continues to accelerate,” said Nitro Chief Product Officer, Sam Thorpe. “Businesses of all sizes, around the world, benefit from the agility, efficiency and productivity eSignature technology enables. And while Nitro delivers a seamless customer experience, as the GigaOm Radar Report attests, there’s far more to our eSignature solutions than just enabling people to sign documents on their devices. Nitro has done the hard work behind the scenes to deliver an easy-to-use, high-trust solution that ensures our customers have the proper security, can avoid fraud and stay compliant.”
GigaOm’s Radar Report notes: “To be a significant player in this space, an e-signature solution must not only support the core e-signature process (preparation, distribution, execution) but also offer extensive compliance support, scalability for high-volume use cases, and flexibility across a range of countries, languages and interfaces. Functionality that simply allows a user to draw a signature on a document is not sufficient to be considered in this report.”
The report adds that “businesses are looking for end-to-end process capabilities rather than standalone solutions. In other words, e-signatures are viewed as a core component of broader document management suites, potentially not something an enterprise would purchase on its own. SMBs will shift more gradually to this strategy but will follow a similar path….”
In its 2023 Radar Report, GigaOm delivers comprehensive evaluations of 14 leading eSignature vendors, an analysis of each of their offerings and provides expert guidance on how to choose the right eSignature vendor for both small and medium business and enterprise requirements.
To read more about Nitro’s position and learn more about what’s happening with eSignatures, click here for a complimentary copy of the GigaOm Radar Report for E-Signature Solutions.
About Nitro Software
Nitro (ASX: NTO) is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its industry-leading analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom